copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Five-year survival in patients with extensive-stage small . . . Abstract Objectives: IMbrella A is a Phase III extension study that allowed rollover from Roche Genentech-sponsored atezolizumab trials, including IMpower133, a Phase I III trial of first-line atezolizumab or placebo plus carboplatin etoposide in extensive-stage small cell lung cancer
The Real-World Outcome of First Line Atezolizumab in . . . Abstract Purpose The addition of immune checkpoint inhibitors to chemotherapy has improved survival outcomes in patients with extensive-stage small cell lung cancer (ES-SCLC) However, their real-world effectiveness remains unknown Therefore, we investigated the effectiveness of atezolizumab plus chemotherapy in ES-SCLC in actual clinical settings Materials and Methods In this multicenter
For Small Cell Lung Cancer, Immunotherapy Drug Improves . . . In a clinical trial of patients with advanced small cell lung cancer (SCLC), atezolizumab (Tecentriq), combined with standard chemotherapy, modestly increased survival—the first trial in more than 20 years to show a survival improvement in this cancer